Interestingly, the melanocytic gene signature was enriched in TARGET neuroblastomas without MYCN amplification but not in St Jude PCGP data (Fig. 2f; Supplementary 2b), probably due to the confounding factors such as different stages, disease risk classification, and pre-treatment and post-treatment from both cohorts. The gene discussed is MYCN; the disease is neuroblastoma.